Would you favor the use of denosumab over bisphosphonate therapy for treatment of osteoporosis in patients who are at high risk for osteoarthritis given recent data suggesting reduced risk of developing knee OA?

Although the overall data to date concerning the impact of denosumab to reduce incident knee OA or lessen established disease remain limited, there are sufficient signals that warrant further investigation and support the need for an appropriately powered RCT with endpoints that include both patient...

This study involved patients aged 45 and older. We only have ten years of denosumab safety data and most bone experts recommend using denosumab in women with osteoporosis aged 65 or older rather than exposing them to denosumab for decades, as we do not know the possible consequences of totally suppr...

"After matching, the 10-year incidence of any OA was 50.8% among denosumab users vs 51.4% among bisphosphonate users, corresponding to an HR of 0.96 (95% CI, 0.94-0.98). Knee OA incidence was 19.2% among denosumab users compared with 21.4% among bisphosphonate users (HR, 0.87; 95% CI, 0.84-0.91). No...